Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05123586 · ClinicalTrials.gov registry record · Phase 2
A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT05123586 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 85 participants.
The verdict
NCT05123586, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
Interventions
- DRUG Placebo
- DRUG LY3361237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2023-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05123586
The ClinicalTrials.gov registry entry for NCT05123586 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05123586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05123586 about?
NCT05123586 is a clinical study titled "A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus". The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
What is the current status of trial NCT05123586?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2022-03-07. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT05123586?
The interventions under investigation include: Placebo (DRUG), LY3361237 (DRUG).
Who is sponsoring clinical trial NCT05123586?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.